SBP-101 / SPARK BioPharma, Handok - LARVOL DELTA

SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: SPARK Biopharma | Active, not recruiting ➔ Recruiting | Trial completion date: Oct 2025 ➔ Dec 2027 | Trial primary completion date: Sep 2025 ➔ Jun 2027

Enrollment open • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • CXCL8 • PD-L1 • S100A8 • S100A9

A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: SPARK Biopharma | Active, not recruiting ➔ Completed

Trial completion

SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: SPARK Biopharma | Trial completion date: Jun 2025 ➔ Oct 2025 | Trial primary completion date: May 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • CXCL8 • PD-L1 • S100A8 • S100A9

A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: SPARK Biopharma | Not yet recruiting ➔ Active, not recruiting

Enrollment closed

A Open-label, Drug-Drug Interaction with SB_MDZ in Healty Adult Subjects (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: SPARK Biopharma

New P1 trial

SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: SPARK Biopharma | Trial primary completion date: Dec 2024 ➔ May 2025

Trial primary completion date • Oncology • Solid Tumor

SB17170 Phase 2 Trial in IPF Patients (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: SPARK Biopharma | Not yet recruiting ➔ Recruiting

Enrollment open • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: SPARK Biopharma | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Oncology • Solid Tumor

SB17170 Phase 2 Trial in IPF Patients (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: SPARK Biopharma

New P2 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

SB17170 Phase1 Trial in Healthy Volunteer (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: SPARK Biopharma | Recruiting ➔ Completed

Trial completion

SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: SPARK Biopharma | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Jan 2024 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • CXCL8 • HMGB1 • PD-L1 • S100A8 • S100A9

SB17170 Phase1 Trial in Healthy Volunteer (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: SPARK Biopharma | Not yet recruiting ➔ Recruiting

Enrollment open • HMGB1 • IFNG • IL6 • TNFA

SB17170 Phase1 Trial in Healthy Volunteer (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: SPARK Biopharma

New P1 trial • HMGB1 • IFNG • IL6 • TNFA

SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: SPARK Biopharma | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • CXCL8 • HMGB1 • PD-L1 • S100A8 • S100A9

SB17170 Phase 1 Clinical Trial in Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: SPARK Biopharma

New P1 trial • Oncology • Solid Tumor • CXCL8 • HMGB1 • PD-L1 • S100A9